# UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - In Vivo Bioassay and Model Development Resource

> **NIH NIH U54** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2023 · $145,309

## Abstract

ABSTRACT (CORE C)
The primary mission of the UAB-Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) is to work with
the PKD Consortium, under the direction of the U24 Central Coordinating Site (U24-CCS) and NIDDK, to
eliminate obstacles in cystic kidney disease research that are slowing progress toward the development of
improved treatment strategies. The UAB-CCKDCC has assembled a multidisciplinary team of researchers that
direct four tightly integrated resource and service-oriented Cores along with an Administrative Core. The
collective mission of these Cores is to support, accelerate, and expand basic and translational research by PKD
Consortium members by providing access to clinical data and biomaterial from CCKD patients, through the
development and distribution of patient-relevant cell and animal models of CCKD to analyze pathogenic
mechanisms involved in cyst initiation and progression, and through the development of streamlined, cost-
effective pipelines for the PKD Consortium to rapidly ascertain the efficacy of new drugs to slow cyst growth.
 The In Vivo Bioassay and Model Development Resource (Core C) within the UAB-CCKDCC is tasked
with generating and distributing animal models, in vivo biosensors and reporter systems for CCKD associated
pathways, and biological reagents generated from these models. Models to be developed include biosensors
and reporters in multiple organisms needed to study signaling pathways involved in CCKD and animal models
for a wide range of CCKD syndromes with human patient mutations that will be generated based on data
obtained in Core A in the UAB-CCKDCC and from the overall PKD Consortium. Core C will also maintain a bank
of biomaterials from these models for distribution to promote pilot studies to rapidly test new hypotheses. Finally,
the wide spectrum of CCKD and reporter systems generated and maintained by Core C will be made readily
available to PKD Consortium for preclinical trails being conducted in Core D of the UAB-CCKDCC to evaluate
candidate therapies using highly standardized, cost-effective, and longitudinal imaging and innovative analysis
strategies. The services and resources being made available by Core C and it’s integration with the other Cores
in the UAB-CCKDCC will expand research activities beyond what is capable in most individual labs and will
accelerate research into possible cures by providing for high quality, robust, and reproducible outcomes that are
critically needed to prioritize drugs for future clinical trials to halt PKD and other cystic kidney disorders.

## Key facts

- **NIH application ID:** 10686003
- **Project number:** 5U54DK126087-04
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Bradley K. Yoder
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $145,309
- **Award type:** 5
- **Project period:** 2020-07-20 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10686003

## Citation

> US National Institutes of Health, RePORTER application 10686003, UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - In Vivo Bioassay and Model Development Resource (5U54DK126087-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10686003. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*